FDA commissioner highlights ‘unanswered questions’ regarding safety of CBD
FDA has many “unanswered questions” when it comes to the safety of cannabidiol (CBD), a cannabis-derived compound, the agency’s top official said last week. FDA Acting Commissioner Norman “Ned” Sharpless, M.D., cited “real risks” and “critical questions” that remain regarding the safety of CBD and tetrahydrocannabinol (THC) in FDA-regulated products, including food and dietary supplements.…
Details